title: Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J pancreatic tumor-bearing mice.
abstract: Liposomes are good candidates as drug carriers and have been widely investigated in drug delivery systems. In this study, a new combination of bimodal 188Re-(DXR)-liposome-BBN radiochemotherapeutics was designed and studied for treating solid pancreatic tumor by intravenous administration. The in vivo nuclear microSPECT/CT imaging of tumor targeting, prolonged survival time and therapeutic efficacy were evaluated in AR42J malignant pancreatic solid tumor-bearing nude mice. MicroSPECT/CT imaging of 188Re-liposome-BBN pointed to significant targeting in tumors at 24 h after intravenous injection (SUV=2.13 ± 0.98). Co-injection of a blocking dose of cold BBN (4 mg/kg) inhibited the accumulation of 188Re-liposome-BBN in tumors (SUV=1.82 ± 0.31). For therapeutic efficacy, inhibition of tumor growth in mice treated with 188Re-DXR-liposome-BBN was precisely controlled [mean growth inhibition rate (MGI) = 0.092] and had longer survival time [life-span (LS) = 86.96%] than those treated with anticancer drug 188Re-liposome-BBN (MGI = 0.130; LS = 75%), Lipo-Dox-BBN (MGI = 0.666; LS = 3.61%) and untreated control mice. An additive tumor regression effect was observed (CI 0.946) for co-delivery of 188Re-DXR-liposome-BBN radiochemotherapeutics. These results point to the potential benefit of the 188Re-(DXR)-liposome-BBN radiochemotherapeutics for adjuvant cancer treatment with applications in oncology.
authors.affiliation: Institute of Nuclear Energy Research, No. 1000 Wenhua Rd., Jiaan Village, Longtan Township, Taoyuan County 32546, Taiwan, ROC.
authors.forename: Ya-Jen
authors.initials: YJ
authors.lastname: Chang
authors.forename: Chia-Yu
authors.initials: CY
authors.lastname: Yu
authors.forename: Chin-Wei
authors.initials: CW
authors.lastname: Hsu
authors.forename: Wan-Chi
authors.initials: WC
authors.lastname: Lee
authors.forename: Su-Jung
authors.initials: SJ
authors.lastname: Chen
authors.forename: Chih-Hsien
authors.initials: CH
authors.lastname: Chang
authors.forename: Te-Wei
authors.initials: TW
authors.lastname: Lee
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D001839:Bombesin / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D059248:Chemoradiotherapy; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D064847:Multimodal Imaging; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000628:therapy*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000494:pharmacology / Q000627:therapeutic use; D012211:Rhenium / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed; D023041:Xenograft Model Antitumor Assays
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D012211:Rhenium; D004317:Doxorubicin; D001839:Bombesin